Program
lorlatinib
Also written as “Lorlatinib”, “PF-06463922” and “Lorlatinib 50 mg”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma · Renal Insufficiency, led by 4 companies.
Drug pageLorlatinib: every studyAll 45 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 173 open or running | phase 4since Apr 22, 2020 | Oct 16, 2013 | Nov 30, 2028NCT06487078 |
| CStone Pharmaceuticals | 11 open or running | phase 2since Mar 17, 2022 | Mar 17, 2022 | none ahead |
| Hoffmann-La Rocheits history only | 11 open or running | phase 1since May 14, 2026 | May 14, 2026 | Aug 31, 2030phase 1 · NCT07617337 |
| Strata Oncologyits history only | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: Merck and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CStone Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2015Named lorlatinibINNProposed as its International Nonproprietary Name in WHO's List 114 · before, PF-06463922
- Mar 17, 2022First study: phase 2 study in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerFirst studyNCT05297890 · 70 enrolled · China
TargetBeta
“An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), ”NCIt, by rule
“ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
Studies
The one study CStone Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer · China | 2 | Active, not recruiting | Dec 26, 2023 | 70 |
How it is read
Names in the registry
- “Lorlatinib”, 10 entries
- “PF-06463922”, 8 entries
- “lorlatinib”, 6 entries
- “Lorlatinib 50 mg”, 1 entry
- “Lorlatinib 75 mg”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Neoplasms, 2 studies
- Carcinoma, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.